Analyst Price Targets — AURA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 5:55 pm | — | Leerink Partners | $17.00 | $7.90 | TheFly | Aura Biosciences price target lowered to $17 from $26 at Leerink |
| March 26, 2025 9:36 am | Jonathan Wolleben | JMP Securities | $19.00 | $5.99 | TheFly | Aura Biosciences price target lowered to $19 from $21 at Citizens JMP |
| March 25, 2025 10:03 am | Edward White | H.C. Wainwright | $25.00 | $7.08 | TheFly | Aura Biosciences price target raised to $25 from $22 at H.C. Wainwright |
| October 18, 2024 7:08 am | George Farmer | Scotiabank | $23.00 | $10.29 | StreetInsider | Aura Biosciences (AURA) PT Raised to $23 at Scotiabank |
| October 18, 2024 6:35 am | Ed White II | H.C. Wainwright | $22.00 | $10.29 | StreetInsider | Aura Biosciences (AURA) PT Raised to $22 at H.C. Wainwright |
| October 18, 2024 5:40 am | Julian Harrison | BTIG | $24.00 | $10.29 | StreetInsider | Aura Biosciences (AURA) PT Raised to $24 at BTIG |
| July 25, 2024 6:06 am | Edward White | H.C. Wainwright | $21.00 | $9.27 | TheFly | Aura Biosciences initiated with a Buy at H.C. Wainwright |
| November 11, 2022 8:43 am | — | JMP Securities | $30.00 | $12.95 | Benzinga | JMP Securities Maintains Market Outperform on Aura Biosciences, Raises Price Target to $30 |
Latest News for AURA
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce complete assay results from the 2026 spring (phase 3) diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario.
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed…
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit.
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company's initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AURA.
U.S. House Trading
No House trades found for AURA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.